The Experts below are selected from a list of 5730 Experts worldwide ranked by ideXlab platform
Robert M. Naclerio - One of the best experts on this subject based on the ideXlab platform.
-
Ipratropium Bromide Increases the Ability of the Nose to Warm and Humidify Air
American Journal of Respiratory and Critical Care Medicine, 2000Co-Authors: P Assanasen, F M Baroody, P Rouadi, E Naureckas, J Solway, Robert M. NaclerioAbstract:We have developed a method for measuring the temperature and relative humidity of air prior to and after nasal conditioning and used it to study the effect of treatment with Ipratropium Bromide on the ability of the nose to condition cold, dry air. We performed randomized, double-blind, placebo-controlled, two-way crossover studies and an open study in nonallergic subjects. The subjects were treated with Ipratropium Bromide (84 μ g) or normal saline solution sprayed into the nasal cavity 15 min before the measurement of nasal conditioning capacity. Cold, dry air was delivered to the nose via a nasal mask, and the temperature and humidity of air were measured before entering and after exiting the nasal cavity. The total water gradient across the nose was calculated and represents nasal conditioning capacity. Ipratropium Bromide treatment significantly increased nasal conditioning capacity when compared with saline. Ipratropium Bromide led to less reduction in the cold, dry air-induced decrease in the nasal...
-
Ipratropium Bromide (atrovent nasal spray) reduces the nasal response to methacholine
The Journal of allergy and clinical immunology, 1992Co-Authors: Fuad M. Baroody, Abraham M. Maichel, Maureen M. Roecker, Paul Roszko, Elena C. Zegarelli, Chester C. Wood, Robert M. NaclerioAbstract:Abstract We investigated the efficacy of local Ipratropium Bromide on methacholine-induced nasal secretions in a double-blind, placebo-controlled experiment. Twenty subjects with perennial rhinitis received a total intranasal dose of 21, 42, 84, and 168 μg of Ipratropium Bromide or placebo in each nostril. One hour later, filter paper disks were used to deliver increasing doses of methacholine and to collect secretions from the left septum. Concomitantly, symptoms of rhinorrhea and nasal congestion were scored. Compared with doses of placebo, all doses of Ipratropium Bromide significantly reduced the methacholine-induced increase in nasal secretion weights and symptoms of rhinorrhea ( p p = 0.01). We speculate that Ipratropium Bromide may prove beneficial for the treatment of rhinorrhea in perennial rhinitis. Furthermore, increasing the delivered dose to 168 μg may increase efficacy without augmenting side effects.
Y Zhao - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Ipratropium Bromide albuterol delivered via respimat inhaler versus mdi
Respiratory Medicine, 2010Co-Authors: Richard Zuwallack, M C De Salvo, T Kaelin, Eric D Bateman, Choonsik Park, R Abrahams, F Fakih, P Sachs, Krishna Pudi, Y ZhaoAbstract:Summary We compared the efficacy and safety of Ipratropium Bromide/albuterol delivered via Respimat ® inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and Ipratropium Respimat ® inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study. Patients with moderate to severe COPD were randomized to Ipratropium Bromide/albuterol (20/100mcg) Respimat ® inhaler, Ipratropium Bromide/albuterol MDI [36mcg/206mcg (Combivent ® Inhalation Aerosol MDI)], or Ipratropium Bromide (20mcg) Respimat ® inhaler. Each medication was administered four times daily. Serial spirometry was performed over 6h (0.15min, then hourly) on 4 test days. The primary efficacy variable was forced expiratory volume in 1s (FEV 1 ) change from test day baseline at 12 weeks. A total of 1209 of 1480 randomized, treated patients completed the study; the majority were male (65%) with a mean age of 64 yrs and a mean screening pre-bronchodilator FEV 1 (percent predicted) of 41%. Ipratropium Bromide/albuterol Respimat ® inhaler had comparable efficacy to Ipratropium Bromide/albuterol MDI for FEV 1 area under the curve at 0–6h (AUC 0–6 ), superior efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 0–4 and comparable efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 4–6 . All active treatments were well tolerated. This study demonstrates that Ipratropium Bromide/albuterol 20/100mcg inhaler ® administered four times daily for 12 weeks had equivalent bronchodilator efficacy and comparable safety to Ipratropium Bromide/albuterol 36mcg/206mcg MDI, and significantly improved lung function compared with the mono-component Ipratropium Bromide 20 mcg Respimat ® inhaler. [Clinical Trial Identifier Number: NCT00400153]
-
Efficacy and safety of Ipratropium Bromide/albuterol delivered via Respimat® inhaler versus MDI
Respiratory medicine, 2010Co-Authors: Richard Zuwallack, M C De Salvo, T Kaelin, Eric D Bateman, Choonsik Park, R Abrahams, F Fakih, P Sachs, Krishna Pudi, Y ZhaoAbstract:Summary We compared the efficacy and safety of Ipratropium Bromide/albuterol delivered via Respimat ® inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and Ipratropium Respimat ® inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study. Patients with moderate to severe COPD were randomized to Ipratropium Bromide/albuterol (20/100mcg) Respimat ® inhaler, Ipratropium Bromide/albuterol MDI [36mcg/206mcg (Combivent ® Inhalation Aerosol MDI)], or Ipratropium Bromide (20mcg) Respimat ® inhaler. Each medication was administered four times daily. Serial spirometry was performed over 6h (0.15min, then hourly) on 4 test days. The primary efficacy variable was forced expiratory volume in 1s (FEV 1 ) change from test day baseline at 12 weeks. A total of 1209 of 1480 randomized, treated patients completed the study; the majority were male (65%) with a mean age of 64 yrs and a mean screening pre-bronchodilator FEV 1 (percent predicted) of 41%. Ipratropium Bromide/albuterol Respimat ® inhaler had comparable efficacy to Ipratropium Bromide/albuterol MDI for FEV 1 area under the curve at 0–6h (AUC 0–6 ), superior efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 0–4 and comparable efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 4–6 . All active treatments were well tolerated. This study demonstrates that Ipratropium Bromide/albuterol 20/100mcg inhaler ® administered four times daily for 12 weeks had equivalent bronchodilator efficacy and comparable safety to Ipratropium Bromide/albuterol 36mcg/206mcg MDI, and significantly improved lung function compared with the mono-component Ipratropium Bromide 20 mcg Respimat ® inhaler. [Clinical Trial Identifier Number: NCT00400153]
Leonard J. Dunn - One of the best experts on this subject based on the ideXlab platform.
-
COPD patient satisfaction with Ipratropium Bromide/albuterol delivered via Respimat: a randomized, controlled study
International journal of chronic obstructive pulmonary disease, 2013Co-Authors: Gary T. Ferguson, Mo Ghafouri, Luyan Dai, Leonard J. DunnAbstract:Background Ipratropium Bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to Ipratropium Bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.
-
copd patient satisfaction with Ipratropium Bromide albuterol delivered via respimat a randomized controlled study
International Journal of Chronic Obstructive Pulmonary Disease, 2013Co-Authors: Gary T. Ferguson, Mo Ghafouri, Luyan Dai, Leonard J. DunnAbstract:Background Ipratropium Bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to Ipratropium Bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.
Mo Ghafouri - One of the best experts on this subject based on the ideXlab platform.
-
copd patient satisfaction with Ipratropium Bromide albuterol delivered via respimat a randomized controlled study
International Journal of Chronic Obstructive Pulmonary Disease, 2013Co-Authors: Gary T. Ferguson, Mo Ghafouri, Luyan Dai, Leonard J. DunnAbstract:Background Ipratropium Bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to Ipratropium Bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.
-
COPD patient satisfaction with Ipratropium Bromide/albuterol delivered via Respimat: a randomized, controlled study
International journal of chronic obstructive pulmonary disease, 2013Co-Authors: Gary T. Ferguson, Mo Ghafouri, Luyan Dai, Leonard J. DunnAbstract:Background Ipratropium Bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to Ipratropium Bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.
-
Ipratropium Bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD.
Chest, 2001Co-Authors: James A. Taylor, Arthur Kotch, Kathryn L. Rice, Mo Ghafouri, Caryn L. Kurland, Nora M. Fagan, Theodore J. WitekAbstract:Study objective To compare the efficacy and safety of Ipratropium Bromide reformulated with the chlorofluorocarbon (CFC)-free propellant hydrofluoroalkane (HFA)-134a (Ipratropium Bromide HFA) to that of the marketed Ipratropium Bromide inhalation aerosol (containing CFC) in patients with COPD. Design This was a randomized, double-blind, parallel-group, placebo-controlled, multicenter trial. The primary efficacy parameter was acute bronchodilator response. The primary end points were peak change in FEV 1 from baseline and area under the response-time curve. Setting Thirty-one clinical centers in the United States participated in this project. Patients A total of 507 patients with moderate-to-severe COPD were randomized, and 444 patients completed the trial. Interventions Twelve weeks of treatment four times daily with one of the following: Ipratropium Bromide HFA, 42 μg; Ipratropium Bromide HFA, 84 μg; HFA placebo; Ipratropium Bromide inhalation aerosol, 42 μg; or CFC placebo. Measurements and results Patients in all active treatment groups had significant bronchodilator responses as shown by increases in mean FEV 1 from baseline of at least 15%. Bronchodilator response in all active treatment groups was also significantly more than their respective placebo treatments based on FEV 1 , area under the time-response curve from 0 to 6 h, and peak response. FVC results were similar to those seen with FEV 1 . There were no significant differences in adverse events, laboratory findings, or ECG findings among the treatment groups. Conclusions Ipratropium Bromide HFA, 42 μg, provided bronchodilation comparable to the marketed Ipratropium Bromide CFC, 42 μg, over 12 weeks of regular use.
Richard Zuwallack - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Ipratropium Bromide albuterol delivered via respimat inhaler versus mdi
Respiratory Medicine, 2010Co-Authors: Richard Zuwallack, M C De Salvo, T Kaelin, Eric D Bateman, Choonsik Park, R Abrahams, F Fakih, P Sachs, Krishna Pudi, Y ZhaoAbstract:Summary We compared the efficacy and safety of Ipratropium Bromide/albuterol delivered via Respimat ® inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and Ipratropium Respimat ® inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study. Patients with moderate to severe COPD were randomized to Ipratropium Bromide/albuterol (20/100mcg) Respimat ® inhaler, Ipratropium Bromide/albuterol MDI [36mcg/206mcg (Combivent ® Inhalation Aerosol MDI)], or Ipratropium Bromide (20mcg) Respimat ® inhaler. Each medication was administered four times daily. Serial spirometry was performed over 6h (0.15min, then hourly) on 4 test days. The primary efficacy variable was forced expiratory volume in 1s (FEV 1 ) change from test day baseline at 12 weeks. A total of 1209 of 1480 randomized, treated patients completed the study; the majority were male (65%) with a mean age of 64 yrs and a mean screening pre-bronchodilator FEV 1 (percent predicted) of 41%. Ipratropium Bromide/albuterol Respimat ® inhaler had comparable efficacy to Ipratropium Bromide/albuterol MDI for FEV 1 area under the curve at 0–6h (AUC 0–6 ), superior efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 0–4 and comparable efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 4–6 . All active treatments were well tolerated. This study demonstrates that Ipratropium Bromide/albuterol 20/100mcg inhaler ® administered four times daily for 12 weeks had equivalent bronchodilator efficacy and comparable safety to Ipratropium Bromide/albuterol 36mcg/206mcg MDI, and significantly improved lung function compared with the mono-component Ipratropium Bromide 20 mcg Respimat ® inhaler. [Clinical Trial Identifier Number: NCT00400153]
-
Efficacy and safety of Ipratropium Bromide/albuterol delivered via Respimat® inhaler versus MDI
Respiratory medicine, 2010Co-Authors: Richard Zuwallack, M C De Salvo, T Kaelin, Eric D Bateman, Choonsik Park, R Abrahams, F Fakih, P Sachs, Krishna Pudi, Y ZhaoAbstract:Summary We compared the efficacy and safety of Ipratropium Bromide/albuterol delivered via Respimat ® inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and Ipratropium Respimat ® inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study. Patients with moderate to severe COPD were randomized to Ipratropium Bromide/albuterol (20/100mcg) Respimat ® inhaler, Ipratropium Bromide/albuterol MDI [36mcg/206mcg (Combivent ® Inhalation Aerosol MDI)], or Ipratropium Bromide (20mcg) Respimat ® inhaler. Each medication was administered four times daily. Serial spirometry was performed over 6h (0.15min, then hourly) on 4 test days. The primary efficacy variable was forced expiratory volume in 1s (FEV 1 ) change from test day baseline at 12 weeks. A total of 1209 of 1480 randomized, treated patients completed the study; the majority were male (65%) with a mean age of 64 yrs and a mean screening pre-bronchodilator FEV 1 (percent predicted) of 41%. Ipratropium Bromide/albuterol Respimat ® inhaler had comparable efficacy to Ipratropium Bromide/albuterol MDI for FEV 1 area under the curve at 0–6h (AUC 0–6 ), superior efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 0–4 and comparable efficacy to Ipratropium Respimat ® inhaler for FEV 1 AUC 4–6 . All active treatments were well tolerated. This study demonstrates that Ipratropium Bromide/albuterol 20/100mcg inhaler ® administered four times daily for 12 weeks had equivalent bronchodilator efficacy and comparable safety to Ipratropium Bromide/albuterol 36mcg/206mcg MDI, and significantly improved lung function compared with the mono-component Ipratropium Bromide 20 mcg Respimat ® inhaler. [Clinical Trial Identifier Number: NCT00400153]
